neoadjuvant chemotherapy-Professor Fernando Figueira Integral Medicine Institute-ovarian cancer

This refers to a specific clinical trial protocol (NCT02249013) developed by the Professor Fernando Figueira Integral Medicine Institute (IMIP) for the treatment of stage III-IV epithelial ovarian cancer with high tumor burden. The regimen consists of neoadjuvant chemotherapy (NACT) using carboplatin and paclitaxel, followed by interval debulking surgery (IDS) combined with short-course Hyperthermic Intraperitoneal Chemotherapy (HIPEC). The HIPEC component involves the administration of cisplatin (with or without doxorubicin) directly into the peritoneal cavity at temperatures of 41-43°C for 30 minutes. Following surgery, patients receive adjuvant chemotherapy with the same carboplatin and paclitaxel combination to complete a total of six systemic cycles. This multimodal approach aims to maximize cytoreduction and target residual microscopic disease through both systemic and localized delivery enhanced by hyperthermia.

Other names

Short-course HIPEC at Interval Debulking SurgeryIMIP HIPEC protocolShort-course Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at Interval Debulking Surgery for High Tumor Burden Ovarian Cancer